RT Journal Article
SR Electronic
T1 Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.27.20081810
DO 10.1101/2020.04.27.20081810
A1 Christoph B. Messner
A1 Vadim Demichev
A1 Daniel Wendisch
A1 Laura Michalick
A1 Matthew White
A1 Anja Freiwald
A1 Kathrin Textoris-Taube
A1 Spyros I. Vernardis
A1 Anna-Sophia Egger
A1 Marco Kreidl
A1 Daniela Ludwig
A1 Christiane Kilian
A1 Federica Agostini
A1 Aleksej Zelezniak
A1 Charlotte Thibeault
A1 Moritz Pfeiffer
A1 Stefan Hippenstiel
A1 Andreas Hocke
A1 Christof von Kalle
A1 Archie Campbell
A1 Caroline Hayward
A1 David J. Porteous
A1 Riccardo E. Marioni
A1 Claudia Langenberg
A1 Kathryn S. Lilley
A1 Wolfgang M. Kuebler
A1 Michael Mülleder
A1 Christian Drosten
A1 Martin Witzenrath
A1 Florian Kurth
A1 Leif Erik Sander
A1 Markus Ralser
YR 2020
UL http://medrxiv.org/content/early/2020/05/03/2020.04.27.20081810.abstract
AB The COVID-19 pandemic is an unprecedented global challenge. Highly variable in its presentation, spread and clinical outcome, novel point-of-care diagnostic classifiers are urgently required. Here, we describe a set of COVID-19 clinical classifiers discovered using a newly designed low-cost high-throughput mass spectrometry-based platform. Introducing a new sample preparation pipeline coupled with short-gradient high-flow liquid chromatography and mass spectrometry, our methodology facilitates clinical implementation and increases sample throughput and quantification precision. Providing a rapid assessment of serum or plasma samples at scale, we report 27 biomarkers that distinguish mild and severe forms of COVID-19, of which some may have potential as therapeutic targets. These proteins highlight the role of complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling upstream and downstream of Interleukin 6. Application of novel methodologies hence transforms proteomics from a research tool into a rapid-response, clinically actionable technology adaptable to infectious outbreaks.Highlights- A completely redesigned clinical proteomics platform increases throughput and precision while reducing costs.- 27 biomarkers are differentially expressed between WHO severity grades for COVID-19.- The study highlights potential therapeutic targets that include complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling both upstream and downstream of interleukin 6.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Ministry of Education and Research (BMBF), as part of the National Research Node ‘Mass spectrometry in Systems Medicine (MSCoresys), under grant agreement 031L0220A. The study was further supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001134), the UK Medical Research Council (FC001134), and the Wellcome Trust (FC001134), and received specific funding from the BBSRC (BB/ N015215/1 and BB/N015282/1) and the Wellcome Trust (200829/Z/16/Z) as well as a Crick Idea to Innovation (i2i) initiative (grant number 10658) (to MR). The Generation Scotland study received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006), and is now supported by the Wellcome Trust (216767/Z/19/Z). Archie Campbell is funded by HDR UK and the Wellcome Trust (216767/Z/19/Z). Caroline Hayward is supported by an MRC University Unit Programme Grant (MC_UU_00007/10) (QTL in Health and Disease). Riccardo Marioni is supported by an Alzheimer’s Research UK project grant (ARUK-PG2017B-10). Leif Erik Sander is supported by the German Research Foundation (DFG, SFB-TR84 114933180) and by the Berlin Institute of Health (BIH), which receives funding from the Ministry of Education and Research (BMBF).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data of the acquired commercial plasma and serum control samples within the GS study was submitted to the ProteomeXchange Consortium via PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset submission #413758. According to the terms of consent for GenerationScotland participants, access to individual-level data (omics and phenotypes) must be reviewed by the GS Access Committee. Applications should be made to access@generationscotland.org.